VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Ruxolitinib in 2022: how this agent has transformed the MF treatment landscape

In this video, Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the role of ruxolitinib in the treatment of myeloproliferative neoplasms (MPNs), drawing focus on how this agent has transformed the treatment landscape of myelofibrosis (MF). Dr Gerds first provides some background information on the development and approval of ruxolitinib, and then goes on to explain how this agent has greatly improved patient outcomes over the years. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter